New treatment for a type of lymphoma caused by Epstein-Barr Virus
EBNA1 Inhibitor for Treatment of EBV-positive DLBCL
This study is looking at a new treatment called VK-2019 for people with a type of cancer called EBV-positive Diffuse Large B-Cell Lymphoma, and it aims to see how safe and effective this treatment is in lowering the virus levels in the blood.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10884413 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for Epstein-Barr Virus (EBV)-positive Diffuse Large B-Cell Lymphoma (DLBCL), a type of cancer that poses a significant health threat globally. The study investigates VK-2019, a first-in-class inhibitor targeting the EBNA1 protein, which is consistently expressed in EBV-related cancers. The approach involves rigorous testing of VK-2019 for its safety, effectiveness, and ability to reduce EBV levels in the blood. Patients may have the opportunity to participate in clinical trials assessing this innovative therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with EBV-positive Diffuse Large B-Cell Lymphoma.
Not a fit: Patients with other types of lymphoma or those without EBV involvement may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for patients with EBV-positive DLBCL.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting viral proteins in cancer treatment, indicating potential for success.
Where this research is happening
Philadelphia, United States
- Wistar Institute — Philadelphia, United States (Active)
Researchers
- Principal investigator: Lieberman, Paul M. — Wistar Institute
- Study coordinator: Lieberman, Paul M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.